Opendata, web and dolomites

HAIKU

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAIKU project word cloud

Explore the words cloud of the HAIKU project. It provides you a very rough idea of what is the project "HAIKU" about.

total    stays    preventive    negative    jobs    social    units    generating    develops    market    hospital    01    infections    cumulative    antibiotics    risk    13    royalties    mission    antibodies    remab    benefit    21    company    portfolio    resistance    natural    families    biotech    therapeutics    14    preventing    first    irr    150    molecule    therapy    class    pharma    finalise    10    drug    care    protection    sales    1000    admitted    icus    antimicrobial       bacteria    addressable    beds    lives    ebitda    consist    patients    removing    icu    mortality    newly    15    prolonged    risked    medicines    removal    multiple    complete    800    de    inhibitory    share    competitors    infectivity    healthcare    days    discount    curing    275    infectious    trials    million    line    intensive    resistant    licensed    created    2026    treatment    morbidity    rate    gram    companies    net    ra    clinical    therapies    23    worldwide    public    price    private    gt    diseases    freeing    group    ph2    240    critical    56    curative    acquired    amr    reduce   

Project "HAIKU" data sheet

The following table provides information about the project.

Coordinator
REMAB THERAPEUTICS SL 

Organization address
address: C FEIXA LLARGA SN EDIFICIO BIOPOL OFFICE 3
city: HOSPITALET DE LLOBREGAT
postcode: 8907
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://remabtx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REMAB THERAPEUTICS SL ES (HOSPITALET DE LLOBREGAT) coordinator 50˙000.00

Map

 Project objective

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.

We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).

RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.

Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients.

RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market

By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAIKU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAIKU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

AI for a faster web (2019)

An automatic approach for creating faster websites using HTTP/2, machine learning, and AI

Read More  

Cancersensing (2019)

A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Read More